ArticleDermatology and therapy2025

Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis.

Melinda J Gooderham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.